Improved anti-cancer effects of luteolinZIF-8 in cervical and prostate cancer cell lines
© 2024 The Authors..
Luteolin, a naturally occurring pharmaceutical compound with significant antitumor properties, faces challenges in clinical applications due to its low solubility in water and limited bioavailability. To address these issues, a one-step synthesis method was employed to encapsulate luteolin within ZIF-8. The successful preparation of luteolinZIF-8 nanoparticles was confirmed through various analytical techniques, including fourier-transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM), laser size distribution analysis, X-ray diffraction (XRD), and release curve assessment. Results indicate that the formulated luteolin@ ZIF-8 nanoparticles exhibited high drug loading (1360 mg/g) and demonstrated selective drug release in acidic microenvironments. Furthermore, the encapsulation of luteolin increased the size of ZIF-8 from 168.4 ± 0.2 nm to 384.7 ± 1.4 nm, but did not change its crystalline structure significantly. Notably, the results of in vitro anti-cervical and prostate cancers experiments revealed that luteolin@ ZIF-8 had better efficacy in inhibiting the proliferation and migration of HeLa and PC3 cells than free luteolin. The antitumor activity of luteolin@ ZIF-8 was sustained for 72 h, with a particularly pronounced inhibitory effect on HeLa cells as compared to PC3 cells. This study underscores the effective enhancement of luteolin's antitumor activity through encapsulation in ZIF-8, offering substantial implications for improving its clinical applications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Heliyon - 10(2024), 6 vom: 30. März, Seite e28232 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ding, Linlin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 26.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.heliyon.2024.e28232 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370141512 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370141512 | ||
| 003 | DE-627 | ||
| 005 | 20240327000208.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.heliyon.2024.e28232 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1349.xml |
| 035 | |a (DE-627)NLM370141512 | ||
| 035 | |a (NLM)38524583 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ding, Linlin |e verfasserin |4 aut | |
| 245 | 1 | 9 | |a Improved anti-cancer effects of luteolinZIF-8 in cervical and prostate cancer cell lines |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Luteolin, a naturally occurring pharmaceutical compound with significant antitumor properties, faces challenges in clinical applications due to its low solubility in water and limited bioavailability. To address these issues, a one-step synthesis method was employed to encapsulate luteolin within ZIF-8. The successful preparation of luteolinZIF-8 nanoparticles was confirmed through various analytical techniques, including fourier-transform infrared spectroscopy (FTIR), transmission electron microscopy (TEM), laser size distribution analysis, X-ray diffraction (XRD), and release curve assessment. Results indicate that the formulated luteolin@ ZIF-8 nanoparticles exhibited high drug loading (1360 mg/g) and demonstrated selective drug release in acidic microenvironments. Furthermore, the encapsulation of luteolin increased the size of ZIF-8 from 168.4 ± 0.2 nm to 384.7 ± 1.4 nm, but did not change its crystalline structure significantly. Notably, the results of in vitro anti-cervical and prostate cancers experiments revealed that luteolin@ ZIF-8 had better efficacy in inhibiting the proliferation and migration of HeLa and PC3 cells than free luteolin. The antitumor activity of luteolin@ ZIF-8 was sustained for 72 h, with a particularly pronounced inhibitory effect on HeLa cells as compared to PC3 cells. This study underscores the effective enhancement of luteolin's antitumor activity through encapsulation in ZIF-8, offering substantial implications for improving its clinical applications | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cervical cancer | |
| 650 | 4 | |a Luteolin | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 4 | |a ZIF-8 | |
| 700 | 1 | |a Chen, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Bi, Guoli |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wenqi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Rui |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Heliyon |d 2015 |g 10(2024), 6 vom: 30. März, Seite e28232 |w (DE-627)NLM255913095 |x 2405-8440 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2024 |g number:6 |g day:30 |g month:03 |g pages:e28232 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.heliyon.2024.e28232 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2024 |e 6 |b 30 |c 03 |h e28232 | ||